


-82-

CLAIMS

1. A compound of formula (I)



5 (I)


wherein

R is H;

Ar is an aromatic group selected from unsubstituted phenyl or phenyl substituted with 1, 2, 3, 4 or 5 substituents selected from C₁-C₄ alkyl, O(C₁-C₄ alkyl), S(C₁-C₄ alkyl),10 halo, and phenyl optionally substituted with halo, C₁-C₄ alkyl or O(C₁-C₄ alkyl);X is unsubstituted phenyl or phenyl substituted with 1, 2, 3, 4 or 5 substituents selected from C₁-C₄ alkyl, O(C₁-C₄ alkyl), and halo;R' is H or C₁-C₄ alkyl;each R¹ is independently H or C₁-C₄ alkyl;15 wherein each above-mentioned C₁-C₄ alkyl group is optionally substituted with one or more halo atoms;

or a pharmaceutically acceptable salt thereof.

2. A compound as claimed in claim 1, represented by formula II:



20 (II)

- 83 -

in which R_2 and R_3 are each independently selected from H, C₁-C₄ alkyl, O(C₁-C₄ alkyl), S(C₁-C₄ alkyl), halo, and phenyl; and

R_4 is selected from H, C₁-C₄ alkyl, O(C₁-C₄ alkyl) and halo;

wherein each above-mentioned C₁-C₄ alkyl group is optionally substituted with one or

5 more halo atoms;

or a pharmaceutically acceptable salt thereof.

3. A compound as claimed in claim 2, wherein R_2 is selected from C₁-C₂ alkyl,

O(C₁-C₂ alkyl), S(C₁-C₂ alkyl), Cl and F wherein each above-mentioned C₁-C₂ alkyl

10 group is optionally substituted with one or more halo atoms.

4. A compound as claimed in claim 2 or claim 3, wherein R_3 is selected from H, Me and Cl.

15 5. A compound as claimed in any one of the claims 2 to 4, wherein R_4 is selected from H, C₁-C₂ alkyl, O(C₁-C₂ alkyl), Cl and F wherein each above-mentioned C₁-C₂ alkyl group is optionally substituted with one or more halo atoms.

6. A compound as claimed in any one of claims 1-5, for use as a pharmaceutical.

20

7. A compound as claimed in any one of claims 1-5, for use as a selective inhibitor of the reuptake of serotonin and norepinephrine.

25 8. The use of a compound as claimed in any one of claims 1-5, for treating a disorder associated with serotonin and norepinephrine dysfunction in mammals.

9. The use of a compound as claimed in any one of claims 1-5, for the manufacture of a medicament for treating a disorder associated with serotonin and norepinephrine dysfunction in mammals.

30

- 84 -

10. A method for selectively inhibiting the reuptake of serotonin and norepinephrine in mammals, comprising administering to a patient in need thereof an effective amount of a compound as claimed in any one of claims 1-5.

5 11. A method for treating a disorder associated with serotonin and norepinephrine dysfunction in mammals, comprising administering to a patient in need thereof an effective amount of a compound as claimed in any one of claims 1-5.

10 12. A method or use as claimed in any one of claims 8, 9 and 11, wherein the disorder is selected from depression, OCD, anxiety, memory loss, urinary incontinence, conduct disorders, ADHD, obesity, alcoholism, smoking cessation and pain.

15 13. A method or use as claimed in any one of claims 8, 9 and 11, wherein the disorder is selected from depression, stress urinary incontinence and pain.

14. A method or use as claimed in any one of claims 8, 9 and 11, wherein the disorder is pain.

15 15. A composition comprising a compound as claimed in any one of claims 1-5 together with a pharmaceutically acceptable diluent, excipient or carrier.